The effect of prediagnostic aspirin use on the prognosis of stage III colorectal cancer

International Journal of Clinical and Experimental Medicine

Volumn 8, Issue 8, 2015, Pages 13435-13445

  Kim, Bun ^a,b   Park, Soo Jung ^a   Hong, Sung Pil ^a   Cheon, Jae Hee ^a   Kim, Won Ho ^a   Kim, Tae Ii ^a  

^a Yonsei University College of Medicine   (South Korea)

^b National Cancer Center   (South Korea)

Author keywords

Aspirin; Colorectal cancer; Prognosis

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLSALICYLIC ACID; CARCINOEMBRYONIC ANTIGEN; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LIPOCORTIN 5; METFORMIN; OXALIPLATIN;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER SPECIFIC SURVIVAL; CANCER STAGING; COLORECTAL CANCER; COLORECTAL CANCER CELL LINE; COMORBIDITY; CONTROLLED STUDY; DISEASE COURSE; FLOW CYTOMETRY; HUMAN; MAJOR CLINICAL STUDY; MICROSATELLITE INSTABILITY; PROGNOSTIC ASSESSMENT; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY;

EID: 84943612225     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Siegel R, Naishadham D and Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11-30.
2. Sung JJ, Lau JY, Goh KL and Leung WK. Increasing incidence of colorectal cancer in Asia: implications for screening. Lancet Oncol 2005; 6: 871-876.
3. Sandler RS, Halabi S, Baron JA, Budinger S, Paskett E, Keresztes R, Petrelli N, Pipas JM, Karp DD, Loprinzi CL, Steinbach G and Schilsky R. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 2003; 348: 883-890.
4. Flossmann E and Rothwell PM. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet 2007; 369: 1603-1613.
5. Algra AM and Rothwell PM. Effects of regular aspirin on long-term cancer incidence and me­tastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol 2012; 13: 518-527.
6. Burn J, Gerdes AM, Macrae F, Mecklin JP, Moeslein G, Olschwang S, Eccles D, Evans DG, Maher ER, Bertario L, Bisgaard ML, Dunlop MG, Ho JW, Hodgson SV, Lindblom A, Lubinski J, Morrison PJ, Murday V, Ramesar R, Side L, Scott RJ, Thomas HJ, Vasen HF, Barker G, Crawford G, Elliott F, Movahedi M, Pylvanainen K, Wijnen JT, Fodde R, Lynch HT, Mathers JC and Bishop DT. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 ran­domised controlled trial. Lancet 2011; 378: 2081-2087.
7. Chan AT, Ogino S and Fuchs CS. Aspirin use and survival after diagnosis of colorectal can­cer. JAMA 2009; 302: 649-658.
8. Rothwell PM, Wilson M, Price JF, Belch JF, Meade TW and Mehta Z. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet 2012; 379: 1591-1601.
9. McCowan C, Munro AJ, Donnan PT and Steele RJ. Use of aspirin post-diagnosis in a cohort of patients with colorectal cancer and its associa­tion with all-cause and colorectal cancer spe­cific mortality. Eur J Cancer 2013; 49: 1049-57.
10. Bastiaannet E, Sampieri K, Dekkers OM, de Craen AJ, van Herk-Sukel MP, Lemmens V, van den Broek CB, Coebergh JW, Herings RM, van de Velde CJ, Fodde R and Liefers GJ. Use of aspirin postdiagnosis improves survival for co­lon cancer patients. Br J Cancer 2012; 106: 1564-1570.
11. Din FV, Theodoratou E, Farrington SM, Tenesa A, Barnetson RA, Cetnarskyj R, Stark L, Porteous ME, Campbell H and Dunlop MG. Effect of aspirin and NSAIDs on risk and sur­vival from colorectal cancer. Gut 2010; 59: 1670-1679.
12. Genetic marker may help target aspirin for colorectal cancer. BMJ 2012; 345: e7281.
13. Schror K. Pharmacology and cellular/molecu­lar mechanisms of action of aspirin and non-aspirin NSAIDs in colorectal cancer. Best Pract Res Clin Gastroenterol 2011; 25: 473-484.
14. Reimers MS, Bastiaannet E, van Herk-Sukel MP, Lemmens VE, van den Broek CB, van de Velde CJ, de Craen AJ and Liefers GJ. Aspirin use after diagnosis improves survival in older adults with colon cancer: a retrospective co­hort study. J Am Geriatr Soc 2012; 60: 2232-2236.
15. Coghill AE, Newcomb PA, Campbell PT, Burnett-Hartman AN, Adams SV, Poole EM, Potter JD and Ulrich CM. Prediagnostic non-steroidal anti-inflammatory drug use and survival after diagnosis of colorectal cancer. Gut 2011; 60: 491-498.
16. Li P, Wu H, Zhang H, Shi Y, Xu J, Ye Y, Xia D, Yang J, Cai J and Wu Y. Aspirin use after diag­nosis but not prediagnosis improves estab­lished colorectal cancer survival: a meta-anal­ysis. Gut 2014; 64: 1419-1425.
17. Liao X, Lochhead P, Nishihara R, Morikawa T, Kuchiba A, Yamauchi M, Imamura Y, Qian ZR, Baba Y, Shima K, Sun R, Nosho K, Meyerhardt JA, Giovannucci E, Fuchs CS, Chan AT and Ogino S. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med 2012; 367: 1596-1606.
18. Almhanna K, El-Rayes B, Sethi S, Dyson G, Heilbrun L, Philip PA and Sarkar F. Association between COX-2 expression and effectiveness of COX-2 inhibitors in a phase II trial in patients with metastatic colorectal adenocarcinoma. Anticancer Res 2012; 32: 3559-3563.
19. Passarelli MN, Coghill AE, Hutter CM, Zheng Y, Makar KW, Potter JD and Newcomb PA. Common colorectal cancer risk variants in SMAD7 are associated with survival among prediagnostic nonsteroidal anti-inflammatory drug users: a population-based study of post­menopausal women. Genes Chromosomes Cancer 2011; 50: 875-886.
20. Claudius AK, Kankipati CS, Kilari RS, Hassan S, Guest K, Russell ST, Perry CJ, Stark LA and Nicholl ID. Identification of aspirin analogues that repress NF-kB signalling and demonstrate anti-proliferative activity towards colorectal cancer in vitro and in vivo. Oncol Rep 2014; 32: 1670-1680.
21. Kim SH, Margalit O, Katoh H, Wang D, Wu H, Xia D, Holla VR, Yang P and DuBois RN. CG100649, a novel COX-2 inhibitor, inhibits colorectal adenoma and carcinoma growth in mouse models. Invest New Drugs 2014; 32: 1105-1112.
22. Moon CM, Kwon JH, Kim JS, Oh SH, Jin Lee K, Park JJ, Pil Hong S, Cheon JH, Kim TI and Kim WH. Nonsteroidal anti-inflammatory drugs sup­press cancer stem cells via inhibiting PTGS2 (cyclooxygenase 2) and NOTCH/HES1 and acti­vating PPARG in colorectal cancer. Int J Cancer 2014; 134: 519-529.
23. Tae II K. Stem cells in colorectal cancer: new potential therapeutic target. Intestinal Research 2013; 11: 85-91.
24. Sipos F, Constantinovits M and Muzes G. Intratumoral functional heterogeneity and chemotherapy. World J Gastroenterol 2014; 20: 2429-2432.